PERSONAL INFORMATION Luca Agnelli

WORK EXPERIENCE

ACADEMIC APPOINTMENTS

01/2014–Present — **Research grant - Post-doc position in bioinformatics and biostatistics research in cancer**

University of Milan - Department of Oncology and Hemato-oncology, Milan (Italy)

Post-doc research grants - art. 22 L. 240/2010:
from 01.01.2014 to 31.12.2014; from 01.01.2015 to 31.12.2015; from 01.01.2016 to 31.12.2016; and from 01.01.2017 to 31.12.2017 on AIRC 5x1000 funds.
from 01.01.2018, on going: on AIRC 2015-2018 IG16722 funds

08/2003–12/2004 — **Fixed-term contract for research activity on hematologic malignancies and bioinformatics**

University of Milan - Deparment of Medical Sciences, Milan (Italy)

Fixed-term project-oriented employement contract - F.I.R.B. fund from Italian Ministry for University and Research on the topic: "Multiple Myeloma: molecular alterations and neoangiogenesis"

OTHER APPOINTMENTS

01/2014–03/2014 — **Fellowship for bioinformatics and biostatistics research in cancer**

Società Italiana Ematologia Sperimentale

Research fellowship on "Integrative genomics and high-throughput sequencing apporaches to unravel relevant micoRNAs in the biology and clinical outcome of multiple myeloma"

01/2011–12/2013 — **Fellowship for bioinformatics and biostatistics research in cancer**

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Felloships on the following topics: "Microarray analysis of deregulated micorRNAs in multiple myeloma associated with disease progression and prognosis" and "Clinical and biological relevance of non-coding sequences (miRNA) in plasma cell dyscrasias"

01/2008–12/2010 — **Fellowship for bioinformatics and biostatistics research in cancer**

F.I.R.C. - Fondazione Italiana Ricerca sul Cancro, Milan (Italy)

Fellowship on the project: "Genome, transcriptome and regulatory networks in multiple myeloma: integrative analysis of microarray data"

01/2005–12/2007 — **Fellowships for research activity in hematologic malignancies and bioinformatics**

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Fellowships on the following topics: "Molecular pathogenesis of multiple myeloma: role of the MMSET gene involved in t(4;14) translocation"; "Global gene expression profiling of multiple myeloma: clinical insights into the bio-diversity of the disease"; "Genomic profiling (array-CGH) and gene expression (GEP) combined analysis for the prognosis and identification of new therapeutic targets: application to

the study of multiple myeloma."

02/2002–07/2003   **Fellowship for research activity on hematologic malignancies**

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (Italy)

Fellowships on the following topics: "Immunophenotypic and molecular genetic study in multiple myeloma and MGUS", "Monitoring of the disease in patients with hematologic malignancies: real-time quantitative PCR analysis of specific genetic lesions"

TEACHING APPOINTMENTS

2008–2010   **Fixed-term contract as Adjunct Professor/External Faculty Member**

University of Milano-Bicocca, Milan (Italy)

Teaching activity:

- for the academic years 2008-2009 lab-assistant in the Immunogenomics course helded by Prof. P. Ricciardi Castagnoli and Dr. F. Zolezzi, University of Milano-Bicocca, Master of Science in Bioinformatics

- for the academic years 2009-2010 Adjunct Professor/External Faculty Member in the Immunogenomics course at the University of Milano-Bicocca, Master of Science in Bioinformatics.

01/2001–06/2001   **Secondary education teaching professional**

Professional Institute "Leonardo Da Vinci", Magenta (Italy)

Temporary vacancy position replacement for Earth Sciences and Biology teaching (18 hours per week) in secondary school.

12/2000–12/2001   **Special education teaching**

NovaCoop, Novara (Italy)

Training in secondary schools and information events on biotechnology in the agro-food field

EDUCATION AND TRAINING

2000   **graduated in Biological Sciences**   110/110 with honors

University of Milan, Milan (Italy)

Title of the study: "Molecular characterization of caveloin in immortalized hypothalamic neurons" - ref. Prof. D. Parolaro, Prof. M. Parenti - attended at the Dept. Pharmacology, Chemotherapy and Medical Toxicology, Milan

POST GRADUATE STUDIES

2014   **PhD in Experimental Hematology**

University of Milan, Milan (Italy)

Title of the study: "Improved risk stratification in multiple myeloma using a microRNA-based classifier", attended at the Dept. Clinical Sciences and Community Health, University of Milan

03/2015   **Advanced training course**

University of Insubria, Varese (Italy)

Next-generation sequencing procedures

03/2012   **Advanced training course**

Istituto Nazionale Tumori, Milan (Italy)

Training course "RNA-seq workshop"

12/2002–01/2003	**Advanced training course**

University of Milano Bicocca, Milano (Italy)

Training course "Data mining and bioinformatics" - Dept. Biotechnology and Biosciences

PERSONAL SKILLS

Mother tongue(s)   Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	C2	C1	C2	C2
Spanish	A2	A2	A2	A2	A2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Job-related skills

Wet lab skills. Molecular biology: gene cloning; polymerase chain reaction (PCR) and Real-Time Quantitative PCR; DNA mutagenesis techniques; DNA sequencing; microarray technology (gene expression, genome, microRNA, methylation profiling). Cell Biology and Biochemistry: Cell cultures; Analysis of transcriptional activity; Analysis of protein expression (immunofluorescence, Western blotting, two-dimensional electrophoresis, subcellular fractioning); confocal microscopy.

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem-solving
Proficient user	Proficient user	Proficient user	Proficient user	Proficient user

Digital skills - Self-assessment grid

Knowledge of Windows OS, Mac OS, Unix/Linux environments. Common tools for home-working, graphics tools and image editing; creating and publishing web pages (HTML and basic notions of PHP languages); reference management software; software and tools for molecular biology; graphical user interface statistical software (SPSS, MedCalc, GraphPad); data-mining software for microarray analysis. Advanced use of R (S-language) and Bioconductor. Basics of bash, Matlab, Phyton, Perl languages. Good knowledge and skills for hardware and devices installation.

Other skills

Theatre practitioner and trainer for informal educations for adults and young people using theatral tecniques.

Driving licence   B

ADDITIONAL INFORMATION

Academic degrees

2014: in the National Scientific Qualification - application 2012, considered as eligibile to be appointed as Associate Professor in the MIUR field codes:
05/F1 (Applied Biology)
05/E2 (Molecular Biology)
06/N1 (Sciences of Health Professions and Applied Medical Technologies)
06/D3 (Blood diseases and Oncology)

Research profile highlights

Summary of research highlights:

Since 2005, I am involved in –*omics* analyses (transcriptome, miRNome, genome, methylome) of, mostly but not exclusively, B- and T-cells hematologic tumors. Recently, I have focused on non-coding RNA world. I have contributed as personnel involved in projects funded by AIRC (IG1194, IG2099, IG4659, IG8675, IG10007 and IG10136, and 5x1000 special program in Molecular Clinical Oncology grants #9965 and #9980). Thanks to this, I have got the opportunity to collaborate with researchers of international relevance in clinical (Prof. G.J. Morgan, NYU, NY, US; Prof. G. Inghirami, Weill Cornell MC, NY, USA; Prof. S. Pileri, IEO, Milan, IT; Prof. G. Tonon, HSR, Milan, IT; Prof. F. Bertoni, IOSI, Bellinzona, CH; Prof G.A.Calin, MD Anderson, TX, US) and biostatistics/bioinformatics fields (Prof. S. Bicciato, Univ of Modena, IT; Prof. S. Bortoluzzi, Univ of Padua, IT). I currently exert peer-review activity for impacted journals and I am a member of the Editorial Board of ncRNA journal. I have been granted with calls as a speaker for lectures (of relevance, invited at the EHA XIV Congress to relate on bioinformatics tools in hemato-oncology research), and for ECM, PhD and University courses (particularly, as an Adjunct professor from 2008 to 2010 in Univ of Milano-Bicocca, MS in Bioinformatics). I currently exert peer-review activity for impacted international journals. I have been considered eligible to be appointed as Associate Professor for the fields 05/F1 (Applied Biology), 05/E2 (Molecular Biology), 06/N1 (Sciences Of Health Professions and Applied Medical Technologies), 06/D3 (Blood diseases and Oncology). Thanks to the research activities in hemato-oncologic fields I have obtained national awards ("Young Researchers" Award 2006, G. Berlucchi Foundation; "Under40 in hematology" award 2013, 3rd placed; Fondazione Bruno Farmaceutici 2014, 3rd placed). To date, I have authored more than 80 peer-reviewed impacted publications and a book chapter.

Academic tutorships

Supervisor for the thesis "Genomic complexity and clinical correlations in Multiple Myeloma: monocentric retrospective study", by Ferla V. Specialization school in Heamatology, University of Milan, academic year: 2016/2017.

Conferences and workshops

Invited speaker at the XIV Congress of the European Hematology Association, Berlin "Bioinformatics tools in the onco-haematological field" - June 4-7, 2009

Invited speaker at the XIII myeloma workshop, Brno (Czech Republic), "Non-coding RNA: new insights in the multiple myeloma transcriptional landscape" - October 24th, 2018

Invited speaker at "Discutiamone Insieme" workshop, Società Italiana Ematologia Sperimentale (SIES), "Nuovi criteri classificativi e/o diagnostici nelle emopatie maligne. Linfomi Non-Hodgkin", Milan, Jun 6th, 2019

Relevant seminars

Invited teacher for the ECM course "Gene expression analysis in the biology and clinical evaluation of multiple myeloma and chronic lymphocityc leukemia", Cosenza (Italy), october 2011

Invited speaker for teaching at the graduate school of Molecular Medicine, University of Milan in the academic year 2011/2012 on "Genomic integrative approach for molecular classification of multiple myeloma"

Invited speaker at "L.A. Seràgnoli" Bologna - Next Generation Sequencing meetings - "The reconstruction of transcriptional regulatory networks reveals critical genes which have implications for clinical outcome of multiple myeloma" – Jan 16th, 2012

Invited speaker at Istituto di Candiolo IRCCS (TO), hosted by Dr. A. Bardelli, "Improved risk stratification in myeloma using a microRNA-based classifier" - Mar 31th, 2016

Invited speaker at IFOM-IEO Campus, hosted by Dr. P.G. Pelicci, "Disentangling the multiple myeloma transcriptional network" - Nov 18th, 2016

Invited speaker at IFOM-IEO Campus, hosted by Dr. G. Testa, "Disentangling the multiple myeloma transcriptional network" - Sep 27th, 2017

Honours and awards

- "Young Researchers" award, 2006, Fondazione G. Berlucchi, for his research activity and the application of high-throughput technogiy in the field of hematology-oncology (http://www.fondazioneberlucchi.com).

- "Under 40 in hematology" award, 2013, 3rd placed, Fondazione Mattioli 1885 (http://www.under40.it/)

- Scientific award, 2014, Fondazione Bruno Farmaceutici, 3rd placed (http://www.brunofarmaceutici.org/)

Editorial and peer-review activity	**Editorial board member**

ncRNA journal
Exploration of Targeted Anti-tumor Therapy

Guest editor

- for the Special issue: "Non coding RNA in Multiple Myeloma" in *ncRNA* journal

- for the Research Issue: "Genomics of Lymphoproliferative Disease" in *Frontiers in Oncology* journal

Reviewer activity for the following international journals:

Molecular Cancer Therapeutics, E-Biomedicine, BMC Cancer, Integrative Cancer Therapies, Oncotarget, Plos ONE, Cancer Medicine, non-codingRNA journal, Carcinogenesis, Cellular Physiology and Biochemistry, Hematological Oncology, Technology in Cancer Research & Treatment, BioMed Research International, Genes, International Journal of Molecular Sciences, Exploration of Targeted Anti-tumor Therapy

Licenses

Author and maintainer of "FBN: FISH Based Normalization and Copy Number inference of SNP microarray data" package for R (Agnelli et al, 2009, Genes Chrom & Cancer) deposited at http://cran.r-project.org/web/packages/FBN/, released under General Public License.

Memberships

Ordinary member of the "Società Italiana di Ematologia Sperimentale" (2010)

Ordinary member of the "Società Italiana di Ematologia" (2018)

Ordinary member of the "Società Italiana di Cancerologia" and the "European Association for Cancer Research" (EACR) (2010)

Projects   **Project involvements:**

Participating as involved personnel to:

- AIRC IG1194 grant "Global gene expression profiling of multiple myeloma: insights into the bio-clinical diversity of the disease" (ys. 2004-2006, 366.000€/3ys)

- AIRC IG4148 grant "Identification of new pathogenetic signals and therapeutic targets of oncogenic ALK " (ys. 2006-2008, 150.000€/3ys)

- AIRC IG4659 grant "Integrative genomic approach to the molecular pathology of multiple myeloma" (ys. 2007-2009, 363.000€/3ys)

- AIRC IG8675 grant "Integrative genomic approach to the molecular pathology of multiple myeloma" (ys. 2009-2011, 240.000€/3ys)

- AIRC IG10136 grant "The role of microRNA in multiple myeloma: biological and clinical implications" (ys. 2010-2012, 462.000€/3ys)

- AIRC IG13358 grant "Identification and characterization of a new subclass of T-NHL: untying the role of ERBB4 in lymphomagenesis " (ys. 2012-2014, 300.000€/3ys)

- AIRC IG16722 grant "The relevance of long non-coding RNAs in the biological and clinical heterogeneity of multiple myeloma" (ys. 2015-2017, 450.000€/3ys)

- AIRC 5x1000 special program Molecular Clincal Oncology grant 2010 "A research platform for miRNA-based treatment of multiple myeloma and chronic lymphocytic leukemia" (12.200.000/5ys)

Publications   **SUMMARY:**

Publications - from 2005 to present: **85**
Books - from 2005 to present: **1**

Hirsch (H) index: **34**. Total Citations: **2731** (source: www.scopus.com as of January 2020)

Chapters in a scientific book:

Neri A, Agnelli L. *The Genomics of Multiple Myeloma and Its Relevance in the Molecular Classification and Risk Stratification of the Disease*. Springer ed., 2013 in: U. Pfeffer (ed.), Cancer Genomics: Molecular Classification, Prognosis and Response Prediction, DOI 10.1007/978-94-007-5842-1

Publications (numbered and reverse-ordered from the most recent)

[2019]

85. Soncini D, Orecchioni S, Ruberti S, Minetto P, Martinuzzi C, Agnelli L, Todoerti K, Cagnetta A, Miglino M, Clavio M, Contini P, Varaldo R, Bergamaschi M, Guolo F, Passalacqua M, Nencioni A, Monacelli F, Gobbi M, Neri A, Abbadessa G, Eathiraj S, Schwartz B, Bertolini F, Lemoli RM, Cea M. The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica. 2019 In press (doi: 10.3324/haematol.2019.224956).

84. Taiana E, Favasuli V, Ronchetti D, Todoerti K, Pelizzoni F, Manzoni M, Barbieri M, Fabris S, Silvestris I, Cantafio MG, Platonova N, Zuccalà V, Maltese L, Soncini D, Ruberti S, Cea M, Chiaramonte R, Amodio N, Tassone P, Agnelli L, Neri A. Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. Leukemia. 2019 In press (doi: 10.1038/s41375-019-0542-5).

83. Chiara M, Primon I, Tarantini L, Agnelli L, Brancaleoni V, Granata F, Bollati V, Di Pierro E. Targeted resequencing of FECH locus reveals that a novel deep intronic pathogenic variant and eQTLs may cause erythropoietic protoporphyria (EPP) through a methylation-dependent mechanism. Genet Med. 2019 In press (doi: 10.1038/s41436-019-0584-0)

82. Storti P, Agnelli L, Dalla Palma B, Todoerti K, Marchica V, Accardi F, Sammarelli G, Deluca F, Toscani D, Costa F, Vicario E, Todaro G, Martella E, Neri A, Giuliani N.. A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma. Haematologica. 2019 In press (doi: 10.3324/haematol.2018.209999)

81. Maura F, Agnelli L*, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P. Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma. Am J Hematol. 2019 Jun;94(6):628-634 * Corresponding author

80. Agnelli L*, Bisognin A, Todoerti K, Manzoni M, Galletti S, Gaffo E, Bortoluzzi S, Neri A. Expanding the repertoire of miRNAs and miRNA-offset RNAs (moRNAs) expressed in multiple myeloma by small RNA deep sequencing. Blood Cancer Journal. Blood Cancer J. 2019 Feb 19;9(3):21. * Corresponding author

[2018]

79. Taiana E, Ronchetti D, Favasuli V, Todoerti K, Manzoni M, Amodio N, Tassone P, Agnelli L, Neri A. Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma. Haematologica. 2019 Feb;104(2):e72-e76

78. Ronchetti D*, Agnelli L*, Pietrelli A, Todoerti K, Manzoni M, Taiana E, Neri A. A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma. Sci Rep. 2018 Apr 26;8(1):6557 * co-authors

77. Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Gallo Cantafio ME, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia (2018) [doi:10.1038/s41375-018-0067-3]

76. Nobili L, Ronchetti D, Agnelli L, Taiana E, Vinci C, Neri A. Long Non-Coding RNAs in Multiple Myeloma. Genes. 2018 Feb 1;9(2). Review.

[2017]

75. Bolzoni M, Ronchetti D, Storti P, Donofrio G, Marchica V, Costa F, Agnelli L, Toscani D, Vescovini R, Todoerti K, Bonomini S, Sammarelli G, Vecchi A, Guasco D, Accardi F, Palma BD, Gamberi B, Ferrari C, Neri A, Aversa F, Giuliani N. IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts. Haematologica. 2017 Apr;102(4):773-784

[2016]

74. Ronchetti D, Manzoni M, Todoerti K, Neri A, Agnelli L*. In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma. Genes 2016 Nov 29;7(12) *Corresponding author

73. Ronchetti D, Manzoni M, Agnelli L, Vinci C, Fabris S, Cutrona G, Matis S, Colombo M, Galletti S, Taiana E, Recchia AG, Bossio S, Gentile M, Musolino C, Di Raimondo F, Grilli A, Bicciato S, Cortelezzi A, Tassone P, Morabito F, Ferrarini M, Neri A. lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome . Blood Cancer J. 2016 Sep 9;6(9):e468

72. Bolzoni M, Chiu M, Accardi F, Vescovini R, Airoldi I, Storti P, Todoerti K, Agnelli L, Missale G, Andreoli R, Bianchi MG, Allegri M, Barilli A, Nicolini F, Cavalli A, Costa F, Marchica V, Toscani D, Mancini C, Martella E, Dall'Asta V, Donofrio G, Aversa F, Bussolati O, Giuliani N. *Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.* Blood,2016 Aug 4; 128(5):667-79

71. Storti P, Marchica V, Airoldi I, Donofrio G, Fiorini E, Ferri V, Guasco D, Todoerti K, Silbermann R, Anderson JL, Zhao W, Agnelli L, Bolzoni M, Martella E, Mancini C, Campanini N, Noonan DM, Petronini PG, Neri A, Aversa F, Roodman GD, Giuliani N. *Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.* Leukemia, 2016 Dec; 30(12):2351-2363

70. Ronchetti D*, Agnelli L*§, Taiana E, Galletti S, Manzoni M, Todoerti K, Musto P, Strozzi F, Neri A. *Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.* Oncotarget, 2016 Mar 22;7(12):14814-30 . *co-authors. § Corresponding author.

69. Minna E, Romeo P, Dugo M, De Cecco L, Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, Greco A, Borrello MG. *miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.* Oncotarget, 2016 Mar 15;7(11):12731-47.

68. Calura E, Bisognin A, Manzoni M, Todoerti K, Taiana E, Sales G, Morgan GJ, Tonon G, Amodio N, Tassone P, Neri A, Agnelli L*, Romualdi C*, Bortoluzzi S*. *Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.* Oncotarget, 2016 Jan 19;7(3):2367-78 . *Corresponding and *co-last author.

67. Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, Circosta P, Abate F, Barreca A, Novero D, Mathew S, Rinaldi A, Tiacci E, Serra S, Deaglio S, Neri A, Falini B, Rabadan R, Bertoni F, Inghirami G, Piva R.: and the European T-cell Lymphoma Study Group. *Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts.* Blood, 2016 Jan 14;127(2):221-32 .

[2015]

66. Simeon V, Todoerti K, Rocca FL, Caivano A, Trino S, Lionetti M, Agnelli L, De Luca L, Laurenzana I, Neri A, Musto P. *Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.* Int J Mol Sci. 2015 Jul 30;16(8):17514-34. Review.

65. Lionetti M, Barbieri M, Todoerti K, Agnelli L, Fabris S, Tonon G, Segalla S, Cifola I, Pinatel E, Tassone P, Musto P, Baldini L, Neri A. *A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias.* Oncotarget. 2015 Sep 22;6(28):26129-41 .

64. Abate F, Todaro M, van der Krogt JA, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A, Novero D, Gaudiano M, Aliberti S, Di Giacomo F, Tousseyn T, Lasorsa E, Crescenzo R, Bessone L, Ficarra E, Acquaviva A, Rinaldi A, Ponzoni M, Longo DL, Aime S, Cheng M, Ruggeri B, Piccaluga PP, Pileri S, Tiacci E, Falini B, Pera-Gresely B, Cerchietti L, Iqbal J, Chan WC, Shultz LD, Kwee I, Piva R, Wlodarska I, Rabadan R, Bertoni F, Inghirami G; and the European T-cell Lymphoma Study Group: Abele C, Bessone L, Barreca A, Boi M, Cavallo F, Chiesa N, Crescenzo R, Fienga A, Gaudiano M, di Giacomo F, Inghirami G, Landra I, Lasorsa E, Marchiorlatti R, Martinoglio B, Medico E, Ferrero GB, Messana K, Mereu E, Pellegrino E, Piva R, Scafò I, Spaccarotella E, Tabbò F, Todaro M, Ubezzi I, Urigu S, Novero D, Chiapella A, Vitolo U, Abate F, Ficarra E, Acquaviva A, Agnelli L, Neri A, Chilosi AC, Zamó A, Facchetti F, Lonardi S, De Chiara A, Fulciniti F, Ferreri A, Ponzoni M, Agostinelli C, Piccaluga PP, Pileri S, Falini B, Tiacci E, Van Loo P, Tousseyn T, De Wolf-Peeters C, Geissinger E, Muller-Hermelink HK, Rosenwald A, Piris MA, Rodriguez ME, Bertoni F, Rinaldi A, Kwee I, Chiattone C, Paes RA. *A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.* Leukemia. 2015 Jun;29(6):1390-401.

63. Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Neri A. *Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.* Oncotarget, 2015 Sep 15;6(27):24205-17.

62. Di Martino MT, Guzzi P, Caracciolo D, Agnelli L, Neri A, Walker B, Morgan G, Cannataro M, Tassone P, Tagliaferri P. *Integrated Analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.* Oncotarget, 2015 Aug 7;6(22):19132-47.

61. Maura F, Cutrona G, Mosca L, Matis S, Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M, Zagatti B, Reverberi D, Gentile M, Recchia AG, Bossio S, Rossi D, Gaidano G, Molica S, Cortelezzi A, Di Raimondo F, Negrini M, Tassone P, Morabito F, Ferrarini M, Neri A. *Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.* Leuk Lymphoma, 2015 May 18:1-9.

60. Maura F, Mosca L, Fabris S, Cutrona G, Matis S, Lionetti M, Agnelli L, Barbieri M, D'Anca M, Manzoni M, Colombo M, Massucco C, Reverberi D, Gentile M, Recchia AG, Bossio S, Ilariucci F, Musolino C, Di Raimondo F, Cortelezzi A, Morabito F, Ferrarini M, Neri A. *Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.* Plos ONE, 2015, 10(3):e0118801.

[2014]

59. Agnelli L, Neri A. *Next-generation sequencing in multiple myeloma: insights into the molecular heterogeneity of the disease.* International Journal of Hematologic Oncology, 2014, 3(5):367-376. *Corresponding author.*

58. Negrini M, Cutrona G, Bassi C, Fabris S, Zagatti B, Colombo M, Ferracin M, D'Abundo L, Saccenti E, Matis S, Lionetti M, Agnelli L, Gentile M, Recchia AG, Bossio S, Reverberi D, Rigolin GM, Calin GA, Sabbioni S, Russo G, Tassone P, Morabito F, Ferrarini M, Neri A. *microRNAome expression in chronic lymphocytic leukemia: comparison with normal B cell subsets and correlations with prognostic and clinical parameters.* Clinical Cancer Research, 2014, 20(15):4141-53.

57. Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, Ten Hacken E, Bertilaccio S, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Ancerson KC, Tonon G. *Rescue of YAP1 triggers DNA damage-induced apoptosis in hematological cancers.* Nature Medicine,2014, 20(6):599-606

56. Hoxha M, Fabris S, Agnelli L, Bollati V, Cutrona G, Matis S, Recchia AG, Gentile M, Cortelezzi A, Morabito F, Bertazzi PA, Ferrarini M, Neri A. *Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.* Genes Chromosomes Cancer, 2014, 53(7):612-21

55. Lionetti M, Fabris S, Cutrona G, Agnelli L, Ciardullo C, Matis S, Ciceri G, Colombo M, Maura F, Mosca L, Gentile M, Recchia AG, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Rossi D, Gaidano G, Morabito F, Ferrarini M, Neri A. *High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukemia: biological and clinical implications.* Br J Hematol, 2014; 165(5):629-39

54. Ronchetti D, Tuana G, Rinaldi A, Agnelli L, Cutrona G, Mosca L, Fabris S, Matis S, Colombo M, Gentile M, Recchia AG, Kwee I, Bertoni F, Morabito F, Ferrarini M, Neri A. *Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia.* Genes Chromosomes Cancer, 2014, 53(3):264-273.

53. Musto P, Simeon V, Martorelli MC, Petrucci MT, Cascavilla N, Di Raimondo F, Caravita T, Morabito F, Offidani M, Olivieri A, Benevolo G, Mina R, Guariglia R, D'Arena G, Mansueto G, Filardi N, Nobile F, Levi A, Falcone A, Cavalli M, Pietrantuono G, Villani O, Bringhen S, Omede P, Lerose R, Agnelli L, Todoerti K, Neri A, Boccadoro M, Palumbo A. *Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.* Leukemia, 2014, 28(1):222-225.

[2013]

52. Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, Zagatti B, Lionetti M, Fabris S, Maura F, Matis S, Gentile M, Vigna E, Colombo M, Massucco C, Recchia AG, Bossio S, De Stefano L, Ilariucci F, Musolino C, Molica S, Di Raimondo F, Cortelezzi A, Tassone P, Negrini M, Monti S, Rossi D, Gaidano G, Ferrarini M, Neri A. *Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.* Clin Cancer Res,2013, 19(21):5890-5900.

51. Todoerti K,* Agnelli L,* Fabris S, Lionetti M, Tuana G, Mosca L, Lombardi L, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Omede P, Tassone P, Boccadoro M, Palumbo A, Neri A, Musto P. *Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.* Clin Cancer Res,2013, 19(12):3247-3258. *co-authors

50. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, Todoerti K, Tuana G, Mosca L, Gallo Cantafio ME, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede P, Morabito F, Tassone P, Boccadoro M, Palumbo A, Neri A. *Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.* Clin Cancer Res,2013, 19(12):3130-3142.

49. Agnelli L, Tassone P, Neri A. *Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.* Expert opinion on biological therapy,2013, 13 Suppl 1:S55-68.

48. Fabris S, Mosca L, Cutrona G, Lionetti M, Agnelli L, Ciceri G, Barbieri M, Maura F, Matis S, Colombo M, Gentile M, Recchia AG, Anna Pesce E, Di Raimondo F, Musolino C, Gobbi M, Di Renzo N, Mauro FR, Brugiatelli M, Ilariucci F, Lipari MG, Angrilli F, Consoli U, Fragasso A, Molica S, Festini G, Vincelli I, Cortelezzi A, Federico M, Morabito F, Ferrarini M, Neri A. *Chromosome 2p gain in*

monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. Am J Hematol,2013, 88(1):24-31.

47. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omede P, Boccadoro M, Palumbo A, Neri A. *Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.* Am J Hematol,2013, 88(1):16-23.

46. Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, Tuana G, Lionetti M, Guercini N, Novella E, Nichele I, Montaldi A, Autore F, Gregorini A, Barcellini W, Callea V, Mauro FR, Laurenti L, Foa R, Neri A, Rodeghiero F, Cortelezzi A. *B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.* Am J Hematol,2013, 88(1):32-36.

45. Bolzoni M, Donofrio G, Storti P, Guasco D, Toscani D, Lazzaretti M, Bonomini S, Agnelli L, Capocefalo A, Dalla Palma B, Neri A, Nicolini F, Lisignoli G, Russo F, Colla S, Aversa F, Giuliani N. *Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.* Leukemia,2013, 27(2):451-463.

44. Storti P, Bolzoni M, Donofrio G, Airoldi I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C, Agnelli L, Patrene K, Maiga S, Franceschi V, Colla S, Anderson J, Neri A, Amiot M, Aversa F, David Roodman G, Giuliani N. *Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.* Leukemia,2013, 27(8):1697-1706.

43. Wu P,* Agnelli L,* Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. *Improved risk stratification in myeloma using a microRNA-based classifier.* Br J Haematol,2013, 162(3):348-359. *co-authors

42. Bolzoni M, Storti P, Bonomini S, Todoerti K, Guasco D, Toscani D, Agnelli L, Neri A, Rizzoli V, Giuliani N. *Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.* Exp Hematol,2013, 41(4):387-397 e381.

41. Ronchetti D, Mosca L, Cutrona G, Tuana G, Gentile M, Fabris S, Agnelli L, Ciceri G, Matis S, Massucco C, Colombo M, Reverberi D, Recchia AG, Bossio S, Negrini M, Tassone P, Morabito F, Ferrarini M, Neri A. *Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.* BMC Med Genomics,2013, 6:27.

[2012]

40. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. *MicroRNAs in the pathobiology of multiple myeloma.* Curr Cancer Drug Targets,2012, 12(7):823-837.

39. Giuliani N, Ferretti M, Bolzoni M, Storti P, Lazzaretti M, Dalla Palma B, Bonomini S, Martella E, Agnelli L, Neri A, Ceccarelli F, Palumbo C. *Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.* Leukemia,2012, 26(6):1391-1401.

38. Agnelli L, Mereu E, Pellegrino E, Limongi T, Kwee I, Bergaggio E, Ponzoni M, Zamo A, Iqbal J, Piccaluga PP, Neri A, Chan WC, Pileri S, Bertoni F, Inghirami G, Piva R, European TCLSG. *Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma.* Blood,2012, 120(6):1274-1281.

37. Visco C, Maura F, Tuana G, Agnelli L, Lionetti M, Fabris S, Novella E, Giaretta I, Reda G, Barcellini W, Baldini L, Neri A, Rodeghiero F, Cortelezzi A. *Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors.* Clin Cancer Res,2012, 18(7):1870-1878.

36. Ronchetti D, Todoerti K, Tuana G, Agnelli L, Mosca L, Lionetti M, Fabris S, Colapietro P, Miozzo M, Ferrarini M, Tassone P, Neri A. *The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma.* Blood cancer journal,2012, 2:e96.

35. Tabbo F, Barreca A, Piva R, Inghirami G, European TCLSG.* *ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.* Frontiers in oncology,2012, 2:41. *collaborators

[2011]

34. Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L, Abeltino M, Todoerti K, Lazzaretti M, Mancini C, Ribatti D, Bonomini S, Franceschi V, Pistoia V, Lisignoli G, Pedrazzini A, Cavicchi O, Neri A, Rizzoli V, Giuliani N. *HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.* Leukemia,2011, 25(3):527-537.

33. Abeltino M, Bonomini S, Bolzoni M, Storti P, Colla S, Todoerti K, Agnelli L, Neri A, Rizzoli V,

Giuliani N. *The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide*. Exp Hematol,2011, 39(1):55-65.

32. Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, Matis S, Grazia Recchia A, Gigliotti V, Gentile M, Deliliers GL, Bertazzi PA, Ferrarini M, Neri A, Baccarelli A. *Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia*. Epigenetics,2011, 6(2):188-194.

31. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S, Neri A. *The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma*. Clin Cancer Res,2011, 17(23):7402-7412. [THIS PAPER RECEIVED EDITORIAL PRESENTATION IN: Clin Cancer Res;17(23):7210-2. Disentangling the myeloma web. Tonon G, Anderson KC]

30. Agnelli L, Storti P, Todoerti K, Sammarelli G, Dalla Palma B, Bolzoni M, Rocci A, Piazza F, Semenzato G, Palumbo A, Neri A, Giuliani N. *Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations*. Am J Hematol,2011, 86(12):E64-66.

29. Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, Kwee I, Bertoni F, Piccaluga PP, Pileri SA, Inghirami G, European TCLSG.* *Anaplastic lymphoma kinase in human cancer. Journal of molecular endocrinology*,2011, 47(1):R11-23. *collaborators

28. Inghirami G, Pileri SA, European TCLSG.* *Anaplastic large-cell lymphoma. Seminars in diagnostic pathology*,2011, 28(3):190-201. *collaborators

27. Biasiolo M, Sales G, Lionetti M, Agnelli L, Todoerti K, Bisognin A, Coppe A, Romualdi C, Neri A, Bortoluzzi S. *Impact of host genes and strand selection on miRNA and miRNA* expression*. PLoS One,2011, 6(8):e23854.

26. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Maggioni M, Agnelli L, Rebulla P, Prati D, Porretti L. *Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma*. PLoS One,2011, 6(6):e21369.

25. Maura F, Cutrona G, Fabris S, Colombo M, Tuana G, Agnelli L, Matis S, Lionetti M, Gentile M, Recchia AG, Di Raimondo F, Musolino C, Ilariucci F, Di Renzo N, Pesce E, Molica S, Federico M, Cortelezzi A, Morabito F, Ferrarini M, Neri A. *Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia*. PLoS One,2011, 6(8):e24313.

[2010]

24. Piva R, Agnelli L, Pellegrino E, Todoerti K, Grosso V, Tamagno I, Fornari A, Martinoglio B, Medico E, Zamo A, Facchetti F, Ponzoni M, Geissinger E, Rosenwald A, Muller-Hermelink HK, De Wolf-Peeters C, Piccaluga PP, Pileri S, Neri A, Inghirami G. *Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms*. J Clin Oncol,2010, 28(9):1583-1590.

23. Giuliani N, Lisignoli G, Novara F, Storti P, Zaffaroni N, Villa R, Sammarelli G, Agnelli L, Todoerti K, Bernardo ME, Manferdini C, Colla S, Abeltino M, Bolzoni M, Rocci A, Gabusi E, Palumbo A, Zuffardi O, Neri A, Rizzoli V. *Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients*. Leukemia,2010, 24(7):1368-1370.

22. Todoerti K, Lisignoli G, Storti P, Agnelli L, Novara F, Manferdini C, Codeluppi K, Colla S, Crugnola M, Abeltino M, Bolzoni M, Sgobba V, Facchini A, Lambertenghi-Deliliers G, Zuffardi O, Rizzoli V, Neri A, Giuliani N. *Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease*. Exp Hematol,2010, 38(2):141-153.

21. Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F, Cutrona G, Andronache A, Matis S, Ferrari F, Gentile M, Spriano M, Callea V, Festini G, Molica S, Deliliers GL, Bicciato S, Ferrarini M, Neri A. *Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion*. Clin Cancer Res,2010, 16(23):5641-5653.

20. Biasiolo M, Forcato M, Possamai L, Ferrari F, Agnelli L, Lionetti M, Todoerti K, Neri A, Marchiori M, Bortoluzzi S, Bicciato S. *Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma*. Pac Symp Biocomput,2010:397-408.

[2009]

19. Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL, Neri A. *Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles*. Genes

Chromosomes Cancer,2009, 48(6):521-531.

18. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, Todoerti K, Verdelli D, Battaglia C, Bertoni F, Deliliers GL, Neri A. *A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect*. Genes Chromosomes Cancer,2009, 48(7):603-614.

17. van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ. *Identification of primary MAFB target genes in multiple myeloma*. Exp Hematol,2009, 37(1):78-86.

16. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, Bortoluzzi S, Neri A. *Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma*. Blood,2009, 114(25):e20-26.

[2008]

15. Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A. *Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia*. Genes Chromosomes Cancer,2008, 47(9):781-793.

14. Pruneri G, Alietti A, Agnelli L, Morabito F, Laszlo D, Calabrese L, Fabris S, Bertolini F, Agazzi A, Bottiglieri L, Raviele PR, Baldini L, Pileri S, Sabattini E, Bosari S, Maisonneuve P, Lambertenghi-Deliliers G, Bertoni F, Martinelli G, Viale G, Neri A. *Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis*. Leuk Res,2008, 32(10):1628-1632.

13. Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S, Deliliers GL, Neri A. *An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma*. BMC Med Genomics,2008, 1:37.

[2007]

12. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, Basso D, Todoerti K, Lombardi L, Lambertenghi-Deliliers G, Neri A. *Transcriptional features of multiple myeloma patients with chromosome 1q gain*. Leukemia,2007, 21(5):1113-1116.

11. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, Kwee I, Rinaldi A, Ronchetti D, Verdelli D, Lambertenghi-Deliliers G, Bertoni F, Neri A. *Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease*. Genes Chromosomes Cancer,2007, 46(3):226-238.

10. Intini D, Agnelli L, Ciceri G, Ronchetti D, Fabris S, Nobili L, Lambertenghi-Deliliers G, Lombardi L, Neri A. *Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma*. Hematol Oncol,2007, 25(1):6-10.

9. Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D, Verdelli D, Callegaro A, Bertoni F, Lambertenghi-Deliliers G, Lombardi L, Neri A. *Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma*. Haematologica,2007, 92(1):56-65.

8. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, Todoerti K, Lambertenghi-Deliliers G, Lombardi L, Neri A. *Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma*. Br J Haematol,2007, 136(4):565-573.

7. Fabris S, Todoerti K, Mosca L, Agnelli L, Intini D, Lionetti M, Guerneri S, Lambertenghi-Deliliers G, Bertoni F, Neri A. *Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma*. Genes Chromosomes Cancer,2007, 46(12):1109-1118.

[2006]

6. Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. *Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes*. J Clin Invest,2006, 116(12):3171-3182.

5. Pruneri G, Ponzoni M, Ferreri AJ, Freschi M, Tresoldi M, Baldini L, Mattioli M, Agnelli L, Govi S, Mancuso P, Agazzi A, Bertolini F, Peccatori J, Bosari S, Gianelli U, Viale G, Neri A. *The prevalence and clinical implications of c-kit expression in plasma cell myeloma*. Histopathology,2006, 48(5):529-535.

[2005]

4. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A. *Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations*. J Clin Oncol,2005,

23(29):7296-7306.

3. Todoerti K, Ronchetti D, Agnelli L, Castellani S, Marelli S, Deliliers GL, Zanella A, Lombardi L, Neri A. *Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma*. Br J Haematol,2005, 131(2):214-218.

2. Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A. *Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.* Genes Chromosomes Cancer,2005, 42(2):117-127.

1. Mattioli M,* Agnelli L,* Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A. *Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma*. Oncogene,2005, 24(15):2461-2473. * co-authors

Disclaimers

Il sottoscritto, consapevole delle sanzioni penali nel caso di dichiarazioni non veritiere e falsità negli atti richiamate dall'art. 76 del D.P.R. 445/2000 e dalle leggi speciali in materia, dichiara la veridicità e la completezza di tutte le informazioni contenute nel Curriculum Vitae. Il sottoscritto esprime altresì il proprio consenso affinché i dati personali forniti possano essere trattati nel rispetto del Decreto legislativo 30.6.2003, n. 196.